FDA Clears First Blood Test for Alzheimer's Disease Pathology

The Alzheimer's Association welcomes the Food and Drug Administration (FDA) clearance of the Elecsys pTau181 plasma test, developed by Roche, marking the first blood-based biomarker test for Alzheimer's disease cleared for use in the primary care setting to rule out the presence of amyloid pathology. This development is expected to improve the diagnostic process by preventing unnecessary specialized testing for individuals whose cognitive issues stem from non-Alzheimer's causes. The test is intended for use in adult patients, aged 55 years and older, presenting with signs or symptoms of cognitive impairment. By providing an efficient, less-invasive method to assess the likelihood of amyloid plaques, this test can help primary care physicians determine which patients do not require Alzheimer's-related follow-up tests.

Key Takeaways:

• The Elecsys pTau181 plasma test is a blood-based biomarker test cleared for use in the primary care setting to rule out Alzheimer's disease pathology.
• The test is designed to identify amyloid plaques, a core hallmark of Alzheimer's disease, but is not a standalone tool for detection or diagnosis.
• The test can help prevent unnecessary specialized testing, such as PET scans or cerebrospinal fluid analysis, for patients with cognitive issues stemming from non-Alzheimer's causes.
• The Alzheimer's Association is committed to ensuring blood tests are used appropriately and effectively across all care settings.
• The Association urges providers to utilize guidance on blood biomarker testing in conjunction with clinical judgement to support effective and appropriate use of these tools.
• The development of this test, along with increased investment in Alzheimer's and dementia research, is expected to accelerate the pace of scientific discovery and lead to better diagnostic tools and effective disease-modifying treatments.

Statistics:

• The Elecsys pTau181 plasma test is intended for use in adult patients, aged 55 years and older.
• The FDA clearance marks the first blood-based biomarker test cleared for use in primary care to rule out Alzheimer's disease pathology.
• According to the Alzheimer's Association, the use of blood tests in specialty care settings and clinical trials has shown promise in identifying individuals with cognitive impairment and assessing their likelihood of having Alzheimer's disease.
• The Association believes that the development of this test, along with historic investment in Alzheimer's and dementia research, will lead to better diagnostic tools and effective disease-modifying treatments.

Sources:

• Food and Drug Administration (FDA) clearance announcement of the Elecsys pTau181 plasma test
• Alzheimer's Association website and news release
• Alzheimer's Association publication of clinical practice guidelines for the use of blood biomarker tests in specialty care settings